---
title: "Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294547324.md"
description: "JonesTrading analyst Debanjana Chatterjee reaffirmed a Buy rating on Contineum Therapeutics (CTNM) with an unchanged $26 price target. The bullish stance is driven by the advancing Phase 2 PROPEL-IPF trial for PIPE-791 and potential validation from Bristol Myers Squibb's ALOFT-IPF study. Additionally, the JNJ-partnered MDD program PIPE-307 offers upside via upcoming MOONLIGHT data."
datetime: "2026-07-31T18:55:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294547324.md)
  - [en](https://longbridge.com/en/news/294547324.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294547324.md)
generator: "portal-rs"
---

# Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on CTNM stock, giving a Buy rating today.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Debanjana Chatterjee has given his Buy rating due to a combination of factors, including the steady advancement of Contineum’s lead IPF program PIPE-791 and a clear line of sight to important validation events. The ongoing Phase 2 PROPEL-IPF trial is enrolling as planned across a broad international footprint, positioning CTNM to benefit from emerging data in a rapidly evolving treatment landscape.

The unchanged $26 price target also reflects the potential derisking from Bristol Myers Squibb’s late-stage ALOFT-IPF study of a similar LPA1 receptor approach, where a favorable readout could strongly support PIPE-791’s mechanism and commercial outlook. In addition, the JNJ-partnered PIPE-307 program in major depressive disorder offers upside optionality, with upcoming Phase 2 MOONLIGHT data that could unlock further value if efficacy is comparable to existing fast-acting antidepressants. 

According to TipRanks, Chatterjee is a 5-star analyst with an average return of 45.6% and a 67.61% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, AbCellera Biologics, and Opus Genetics.

### Related Stocks

- [CTNM.US](https://longbridge.com/en/quote/CTNM.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md)
- [ABCL.US](https://longbridge.com/en/quote/ABCL.US.md)
- [IRD.US](https://longbridge.com/en/quote/IRD.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Contineum Therapeutics: Buy Rating Reiterated with PIPE-791 Upside Potential and Unchanged $26 Price Target](https://longbridge.com/en/news/297799155.md)
- [232,697 Shares in Bristol Myers Squibb Company $BMY Acquired by Beacon Pointe Advisors LLC](https://longbridge.com/en/news/297394340.md)
- [Trajan Wealth LLC Has $10.13 Million Stake in Johnson & Johnson $JNJ](https://longbridge.com/en/news/298127700.md)
- [A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths](https://longbridge.com/en/news/298057100.md)
- [Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns](https://longbridge.com/en/news/298117865.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**